US Patent 11926636 Crystalline forms of lorlatinib maleate
Patent 11926636 was granted and assigned to Pfizer on March, 2024 by the United States Patent and Trademark Office.
All edits
Edits on 14 Mar, 2024
Golden AI
Edits made to:
Infobox (+18 properties)
Article (+474 characters)
US Patent 11926636 Crystalline forms of lorlatinib maleate
Article
Patent abstract
This invention relates to new crystalline forms of (10R)-7-amino-12-fluoro-2,10,16-trimethyl-15-oxo-10,15,16,17-tetrahydro-2H-8,4-(metheno)pyrazolo[4,3-h][2,5,11]benzoxadiazacyclotetradecine-3-carbonitrile(lorlatinib) maleate. The invention also relates to pharmaceutical compositions comprising lorlatinib maleate, and to methods of using lorlatinib maleate and compositions comprising it in the treatment of abnormal cell growth, such as cancer, in mammals.
Infobox
Is a
Patent Applicant
Current Assignee
Patent Jurisdiction
Patent Number
Patent Inventor Names
Klimentina Dimitrova Pencheva0
Date of Patent
March 12, 2024
0Patent Application Number
173652700
Date Filed
July 1, 2021
0Patent Citations
Patent Primary Examiner
CPC Code
Find more entities like US Patent 11926636 Crystalline forms of lorlatinib maleate
Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.
